WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2009134086) PHARMACEUTICAL FORMULATION FOR TREATMENT OF CARDIOVASCULAR DISEASE
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2009/134086    International Application No.:    PCT/KR2009/002278
Publication Date: 05.11.2009 International Filing Date: 29.04.2009
IPC:
A61K 9/22 (2006.01), A61K 9/00 (2006.01), A61K 9/48 (2006.01), A61K 9/16 (2006.01), A61K 31/44 (2006.01)
Applicants: HANALL BIOPHARMA CO., LTD [KR/KR]; 400-1 Sangseo-dong Daedeok-gu Daejeon 306-120 (KR) (For All Designated States Except US).
KIM, Sung Wuk [KR/KR]; (KR) (For US Only).
JUN, Sung Soo [KR/KR]; (KR) (For US Only).
JO, Young Gwan [US/KR]; (KR) (For US Only).
KOO, Ja Seong [KR/KR]; (KR) (For US Only).
LEE, Ah Ram [KR/KR]; (KR) (For US Only).
SON, Jae Woon [KR/KR]; (KR) (For US Only).
PARK, Yun Sang [KR/KR]; (KR) (For US Only).
KIM, Byung Ha [KR/KR]; (KR) (For US Only).
NAM, Tae Young [KR/KR]; (KR) (For US Only).
CHOI, Jin Won [KR/KR]; (KR) (For US Only)
Inventors: KIM, Sung Wuk; (KR).
JUN, Sung Soo; (KR).
JO, Young Gwan; (KR).
KOO, Ja Seong; (KR).
LEE, Ah Ram; (KR).
SON, Jae Woon; (KR).
PARK, Yun Sang; (KR).
KIM, Byung Ha; (KR).
NAM, Tae Young; (KR).
CHOI, Jin Won; (KR)
Agent: AHN, So-Young; Dr. Ahn International Patent Law Office 10th Fl., Shinseung Bldg. 1676-1 Seocho-dong, Seocho-gu Seoul 137-881 (KR)
Priority Data:
10-2008-0039864 29.04.2008 KR
Title (EN) PHARMACEUTICAL FORMULATION FOR TREATMENT OF CARDIOVASCULAR DISEASE
(FR) PRÉPARATION PHARMACEUTIQUE POUR LE TRAITEMENT D'UNE MALADIE CARDIOVASCULAIRE
(KO) 심혈관계 질환 치료용 약제학적 제제
Abstract: front page image
(EN)The present invention provides (1) a release-controlled pharmaceutical formulation including a Simvastatin-containing early release compartment and a Losartan-containing retarded release compartment, (2) a release-controlled pharmaceutical formulation including a Simvastatin-containing early release compartment and an Olmesartan-containing retarded release compartment, (3) a release-controlled pharmaceutical formulation including a Simvastatin-containing early release compartment and a Valsartan-containing retarded release compartment, (4) a release-controlled pharmaceutical formulation including a Simvastatin-containing early release compartment and a Candesartan-containing retarded release compartment, (5) a release-controlled pharmaceutical formulation including a Rosuvastatin-containing early release compartment and a Losartan-containing retarded release compartment, (6) a release-controlled pharmaceutical formulation including a Rosuvastatin-containing early release compartment and an Iresartan-containing retarded release compartment, and (7) a release-controlled pharmaceutical formulation including a Rosuvastatin-containing early release compartment and a Candesartan-containing retarded release compartment. The pharmaceutical formulation of the present invention minimizes an antagonism between drugs and side effects of the drugs and maximizes unique effects of drugs because different drugs contained in different compartments in the formulation are released with a time difference. The pharmaceutical formulation of the present invention prepared by the specific combination of two drugs exhibits remarkably excellent effects of treatment or prevention of disease as compared with a single medication or a simply combined medication.
(FR)La présente invention concerne: 1) une préparation pharmaceutique à libération contrôlée comprenant un constituant à base de simvastatine à libération précoce et un constituant à base de losartan à libération retardée; 2) une préparation pharmaceutique à libération contrôlée comprenant un constituant à base de simvastatine à libération précoce et un constituant à base d'olmésartan à libération retardée; 3) une préparation pharmaceutique à libération contrôlée comprenant un constituant à base de simvastatine à libération précoce et un constituant à base de valsartan à libération retardée; 4) une préparation pharmaceutique à libération contrôlée comprenant un constituant à base de simvastatine à libération précoce et un constituant à base de candésartan à libération retardée; 5) une préparation pharmaceutique à libération contrôlée comprenant un constituant à base de rosuvastatine à libération précoce et un constituant à base de losartan à libération retardée; 6) une préparation pharmaceutique à libération contrôlée comprenant un constituant à base de rosuvastatine à libération précoce et un constituant à base d'irbésartan à libération retardée; et 7) une préparation pharmaceutique à libération contrôlée comprenant un constituant à base de rosuvastatine à libération précoce et un constituant à base de candésartan à libération retardée. La préparation pharmaceutique de l'invention réduit au minimum un antagonisme entre des médicaments et des effets secondaires, et optimise les effets singuliers de médicaments liés au fait que différents médicaments présents dans les autres constituants de la préparation sont libérés de manière décalée. La préparation pharmaceutique de l'invention, qui est obtenue par la combinaison spécifique de deux médicaments, agit avec une efficacité remarquable dans le traitement ou la prévention d'une maladie, par comparaison avec une médication simple ou une médication de combinaison simple.
(KO)본 발명은 (1) 심바스타틴을 함유하는 선방출성 구획과 로자탄을 함유하는 지연방출성 구획을 포함하는 약제학적 제제, (2) 심바스타틴을 함유하는 선방출성 구획과 올메사르탄을 함유하는 지연방출성 구획을 포함하는 약제학적 제제, (3) 심바스타틴을 함유하는 선방출성 구획과 발사르탄을 함유하는 지연방출성 구획을 포함하는 약제학적 제제, (4) 심바스타틴을 함유하는 선방출성 구획과 칸데사르탄을 함유하는 지연방출성 구획을 포함하는 약제학적 제제, (5) 로슈바스타틴을 함유하는 선방출성 구획과 로자탄을 함유하는 지연방출성 구획을 포함하는 약제학적 제제, (6) 로슈바스타틴을 함유하는 선방출성 구획과 이베사르탄을 함유하는 지연방출성 구획을 포함하는 약제학적 제제, (7) 로슈바스타틴을 함유하는 선방출성 구획과 칸데사르탄을 함유하는 지연방출성 구획을 포함하는 약제학적 제제를 제공한다. 본 발명의 약제학적 제제는 제제 내 다른 구획내 포함된 상이한 약물이 시간차를 두고 방출됨으로써 약물 상호간 길항작용 및 부작용을 최소화하고, 약물 본래의 효과를 최대화한다. 본 발명의 두가지 약물의 특정 조합에 의한 약제학적 제제는, 각각의 단독 투여 및 단순 복합 투여에 비하여 현저히 우수한 질환의 치료 내지 예방 효과를 나타낸다.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: Korean (KO)
Filing Language: Korean (KO)